EUSA to buy Cytogen for $22mm in cash
Privately held specialty pharmaceuticals start-up EUSA Pharma has agreed to buy public cancer and pain therapeutics developer Cytogen in an all-cash deal valued at about $22mm.
- Medical Devices
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.